Florbenazine F18

Drug Profile

Florbenazine F18

Alternative Names: 18F-DTBZ; 18F-AV-133; 18F-FP-Dihydrotatetrabenazine; 18F-FP-DTBZ; AV-133; VMAT2 imaging - Avid Radiopharmaceuticals

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan; University of Pennsylvania
  • Developer Avid Radiopharmaceuticals; Chang Gung Memorial Hospital
  • Class Contrast media; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Parkinsonian disorders
  • Phase II/III Parkinson's disease
  • No development reported Diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetes-mellitus(Diagnosis) in USA (IV, Injection)
  • 01 Mar 2016 Avid Radiopharmaceuticals completes a phase II/III trial in Parkinson's disease (Diagnosis) in Australia and USA (IV) (NCT01550484)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top